Why Oncology Trials Struggle With Recruitment and How Patiro Solves It
Oncology patient recruitment rarely fails because there are not enough patients. It fails because the patients who see the study are not eligible, the timing does not match the treatment decision window, or sites get flooded with low-quality inquiries they cannot work.
Oncology protocols narrow eligibility fast. Prior lines of therapy, ECOG status, comorbidities, washout periods, and biomarker status eliminate most responders. Many patients learn about trials after a new regimen has already started, when switching is not clinically realistic.
Why Oncology Patient Recruitment Breaks Down in Real Studies
Many oncology trials live or die on referral pathways, not awareness. When outreach does not connect to those pathways, patients self-refer too late, sites spend time screening mismatches, and enrollment slows.
Logistics decide who can participate even when the protocol fits. Travel, visit frequency, imaging schedules, caregiver availability, and time off work affect consent and retention. Published research points to clear drivers: clearer communication, lower logistical burden, and using digital channels patients already use.
Patiro's Expertise in Oncology Clinical Trials
Patiro supports oncology clinical trial recruitment with a focus on qualified referrals and site-ready pre-screening, not lead volume. We build indication-specific targeting and messaging that reflects the real inclusion and exclusion criteria, then route only likely-fit candidates into site workflows.
Patiro has supported patient recruitment for clinical trials across a broad range of oncological conditions, from hematological malignancies to gastrointestinal cancers, spanning common diagnoses through to rare and ultra-rare disease indications.
In hematological oncology, Patiro has recruited for trials investigating B-cell malignancies, Follicular Lymphoma, Polycythemia Vera, Myelofibrosis, and Myelodysplastic Syndromes (MDS) among others. These conditions range from relatively prevalent blood cancers to rare myeloid disorders where eligible patient populations are small, geographically dispersed, and difficult to reach through conventional recruitment methods.
In solid tumor oncology, Patiro has supported recruitment for Gastroesophageal Adenocarcinoma trials, a challenging indication defined by strict eligibility criteria, complex staging requirements, and patients who are often managing active treatment alongside trial participation.
We work with sites to protect coordinator time, because capacity is often the real bottleneck. We support retention with structured follow-up and patient communication that respects treatment urgency and the emotional context of a cancer diagnosis.
Why Partner With Patiro for Your Oncology Trial?
Patiro supports sponsors and CROs with global full-service and tailored FSP options across recruitment and site support. We run multi-channel outreach, including digital campaigns, and we use Facebook advertising when it fits the patient population and country rules.
Our site network spans more than 2,000 clinical sites across 44 countries. Sponsors get real-time visibility through a management platform that shows recruitment and site performance. By collaborating with Patiro, you’ll be partnering with an experienced recruitment team that supports every phase of your trial. From recruitment to retention, we are dedicated to accelerating your timeline while ensuring compliance with all regulatory requirements.
You can also choose a Pay Only per Enrolled Patient model to reduce financial risk and keep accountability tied to enrollment. Patiro’s retention support has shown a 65% reduction in attrition and 40% faster recruitment timelines based on case studies.
Contact us to discuss how we can help with clinical trial recruitment for your oncology trial.
Frequently Asked Questions
How fast can you start oncology patient recruitment?
Launch timing depends on protocol clarity, geographies, and the site plan. Patiro can mobilise quickly once pre-screening and referral pathways are confirmed. With experience supporting oncology rescue studies where enrollment had already fallen behind, Patiro knows how to move fast without compromising referral quality.
How does Patiro reduce screen failures in oncology trials?
Patiro reduces screen failures in oncology trials by pre-screening against protocol criteria and route site-ready candidates, so sites spend less time on obvious mismatches.
Can Patiro support biomarker-driven or rare oncology trials?
Yes, Patiro supports biomarker-driven and rare oncology trials. We plan outreach around narrow eligibility, specialist pathways, and geography so referral flow matches the trial reality.
Does Patiro support beyond lead generation?
Yes. We support site coordination, referral management, and retention communication through enrollment.
How do you reduce burden on oncology sites?
We reduce the site burden by handling patient outreach, pre-screening, and structured follow-up so site teams can focus on clinical work.
Can you recruit diverse populations across regions?
Yes, we localize language and creative by country and channel, while keeping criteria handling consistent so sites receive leads screened to the same standard.
How does pricing work for oncology trials?
Patiro offers a pay-per-enrolled-patient model, meaning sponsors pay for enrolled participants rather than referral volume. This keeps budget risk low and aligns Patiro's incentives directly with the sponsor's enrollment goals.
